Clinical utility of adjunctive high-risk human Papillomavirus DNA testing in women with papanicolaou test findings of atypical glandular cells

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 1, 2010, Pages 103-108

  Zhao, Chengquan ^a   Florea, Anca ^a   Austin, R Marshall ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADENOCARCINOMA; ADULT; AGE; AGED; ARTICLE; CARCINOMA IN SITU; ENDOMETRIUM TUMOR; FEMALE; GENETICS; HUMAN; MIDDLE AGED; OVARY TUMOR; PAPILLOMA VIRUS; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PAPILLOMAVIRIDAE; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 75149160578     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Simsir A, Hwang S, Cangiarella J, et al. Glandular cell atypia on Papanicolaou smears: interobserver variability in the diagnosis and prediction of cell of origin. Cancer. 2003;99(6):323-330.
2. Lee KR, Daragh TM, Joste NE, et al. Atypical glandular cells of undetermined significance (AGUS): Interobserver reproducibility in cervical smears and corresponding thin-layer preparations. Am J Clin Pathol. 2002;117(1): 96-102.
3. Andrae B, Kermetli L, Sparen P, et al. Screening preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008; 100(9):622-629.
4. The International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2006;120(4): 885-891.
5. Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer. 2003;99(6):336-341.
6. Kinney W, Sawaya G, Sung H, Kearney K, Miller M, Hiatt RA. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cervical screening. Acta Cytol. 2003;47(2):167-171.
7. Herbert A, Singh N, Smith JAE. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12 year study in Southampton and South-west Hampshire. Cytopathology. 2001;12(1):26-36.
8. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol. 2006;107(3):701-708.
9. Haidopoulos DA, Stefanidis K, Rodolakis A, Pilalis A, Symiakaki I, Diakomanolis E. Histologic implications of Pap smears classified as atypical glandular cells. J Reprod Med. 2005;50(3):539-542
10. Chhieng DC, Cangiarella JF. Atypical glandular cells. Clin Lab Med. 2003; 23(3):633-657.
11. Wood MD, Horst JA, Bibbo M. Weeding atypical glandular cell lookalikes from the true atypical lesions in liquid-based Pap tests: a review. Diagn Cytopathol. 2007;35(1):12-17.
12. Chichareon SB, Tocharoenvanich S. Risk factors of having high-grade cervical intraepithelial neoplasia/invasive carcinoma in women with atypical glandular cells of undetermined significance smears. Int J Gynecol Cancer. 2006; 16(2):568-574.
13. Gurbuz A, Karateke A, Kabaca C, Kir G. Atypical glandular cells: improvement in cytohistologic correlation by the 2001 Bethesda system. Int J Gynecol Cancer. 2005;15(5):903-910.
14. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol. 2005;105(3):494-500.
15. Torres JC, Derchain SF, Gontijo RC. Atypical glandular cells: criteria to discriminate benign from neoplastic lesions and squamous from glandular neoplasia. Cytopathology. 2005;16(6):295-302.
16. Barreth D, Faught W, Schepansky A, Johnson G. The relationship between atypical glandular cells of undetermined significance on Pap smear and a clinically significant histologic diagnosis. J Obstet Gynaecol Can. 2004;26(10): 867-870.
17. Chhieng DC, Gallaspy S, Yang H, Roberson J, Eltoum I. Women with atypical glandular cells: a long-term follow-up study in a high-risk population. Am J Clin Pathol. 2004;122(4):575-579.
18. Scheiden R, Wagener C, Knolle U, Dippel W, Capesius C. Atypical glandular cells in conventional cervical smears: incidence and follow-up. BMC Cancer. 2004;4:37.
19. Cangiarella JF, Chhieng DC. Atypical glandular cells-an update. Diagn Cytopathol. 2003;29(5):271-279.
20. Jeng CJ, Liang HS, Wang TY, Shen J, Yang YC, Tzeng CR. Cytologic and histologic review of atypical glandular cells (AGC) detected during cervical cytology screening. Int J Gynecol Cancer. 2003;13:518-521.
21. Smith HO, Benwick M, Qualls CF, Verschraegen CF, Wiggins C. Thirtyyear trends in cervical cancer incidence rates: a surveillance, epidemiology, and end results program population-based study. In: Plenary Sessions Compendium of the Annual Meeting on Women's Cancer from the Society of Gynecologic Oncologists; March 4-7, 2007; San Diego, CA. Abstract 196.
22. Linder J, Keene J, Sheets E. Cervical cancer reduction through higher sensitivity Pap testing: observed vs. calculated effects. Cancer. 2007;111:369.
23. Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004;128(11):1224-1229.
24. Chen L, Yang B. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. Cancer. 2008; 114(4):236-241.
25. Rabelo-Santos SH, Derchain SFM, do Amaral Westin MC, et al. Endocervical glandular cell abnormalities in conventional cervical smears: evaluation of the performance of cytomorphological criteria and HPV testing in predicating neoplasia. Cytopathology. 2008;19(1):34-43.
26. Costa S, Negri G, Sideri M, et al. Human papillomavirus (HPV) test and Pap smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol. 106(1):170-176.
27. Diaz-Montes TP, Farinola MA, Zahurak ML, Bristow RE, Rosenthal DL. Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecologic Oncol. 2007;104(2): 366-371.
28. Oliveira ER, Derchain SF, Sarian LO, et al. Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities. Int J Gynecol Cancer. 2006;16(3):1055-1062.
29. Saqi A, Gupta PK, Eroll M, et al. High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. Diagn Cytopathol. 2006;34(3):235-239.
30. Fetterman B, Shaber R, Pawlick G, Kinney W. Human papillomavirus testing in routine clinical practice for prediction of underlying cervical intraepithelial neoplasia 2/3+ at initial evaluation and in follow-up of women with atypical glandular cell Papanicolaou tests. J Lower Gen Tract. 2006;10(3): 1078-1079.
31. Werner CL, Griffith WF, West AM, Ashfaq R. Reflex human papillomavirus DNA testing of atypical glandular cell cervical cytologies [abstract]. J Lower Gen Tract. 2006;10(3):179.
32. Irvin W, Evans SR, Andersen W, et al. The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol. 2005;193(2):559-567.
33. Oliveira ER, Derchain SF, Rabelo-Santos SH, et al. Detection of high-risk human papillomavirus (HPV) DNA by hybrid capture II in women referred due to atypical glandular cells in the primary screening. Diagn Cytopathol. 2004;31(1): 19-22.
34. Krane JF, Lee KR, Sun D, Yuan L, Crum CP. Atypical glandular cells of undetermined significance: outcome predictions based on human papillomavirus testing. Am J Clin Pathol. 2004;121(1):87-92.
35. Derchain SFM, Rabelo-Santos SH, Sarian LO, et al. Human papillomavirus detection and histologic findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol. 2004;95:618-623.
36. Rowe LR, Aldeen W, Bentz JS. Prevalence and typing of HPV DNA by hybrid capture II in women with ASCUS, ASC-H, LSIL, and AGC on ThinPrep Pap tests. Diagn Cytopathol. 2004;30(6):426-432.
37. Ronnett BM, Manos MM, Ramsley JE, et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol. 1999;30(7): 816-825.
38. Guidos R, Schiffman M, Solomon D, Burke L. Postcolposcopy management strategies for women referred with low grade squamous intraepithelial lesions or human papillomavirus-positive atypical squamous cells of undetermined significance: a two year prospective study. Am J Obstet Gynecol. 2003; 188(6):1401-1405.
39. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-2119.
40. Reuss E, Price J, Koonings P. Atypical Glandular cells of undetermined significance: subtyping as a predictor of outcome. J Reprod Med. 2001;46(8): 701-775.
41. Simsir A, Hwang S, Cangiarella J, et al. Glandular cell atypia on Papanicolaou smears: interobserver variability in the diagnosis and predication of the cell of origin. Cancer. 2003;99(6):323-330.
42. Barreth D, Faught W, Schepansky A, et al. The relationship between atypical glandular cells of undetermined significance on pap smear and a clinically significant histologic diagnosis. J Obstet Gynaecol Can. 2004;26(10): 867-870.
43. DeSimone CP, Day ME, Towar MM, et al. Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol. 2006;107(6):1285-1291.
44. Holland-Barkis P, Forjuoh SN, Couchman GR, et al. Primary care physicians' awareness and adherence to cervical cancer screening guidelines in Texas. Prev Med. 2006;42(2):140-145.
45. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Lack of adherence to practice guidelines for women with atypical glandular cells on cervical cytology. Obstet Gynecol. 2005;105(3):501-506.
46. Noller KL, Bettes B, Zinberg S, Schulkin J. Cervical cytology screening practices among obstetricians-gynecologists. Obstet Gynecol. 2003;102(2):259-265.
47. US Census Bureau. American Community Survey (ACS) Web site. http://www.census.gov/acs/www/. Accessed December 1, 2008.
48. Dzura B, Quinn S, Richard K. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the cervix. Acta Cytol. 2006;50(3):309-311.
49. Castle PE, Lorincz AT, Scott DR, et al. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol. 2003;41(9):4022-4030.
50. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492-501.
51. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516-520.
52. Andersson S, Rylander E, Larson B, et al. Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol Rep. 2003; 10(1):175-179.
53. Andersson S, Larson B, Hjerpe A, et al. Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand. 2003;82(10):960-965.
54. Ferenczy A. Cervical cancer screening: the blessing of molecular technology. HPV Today. 2008;15:1-4.
55. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2008;124(3):516-520.
56. Wright T. Cervical Cancer Screening in the 21st Century: is it time to retire the Pap? Clin Gynecol Obstet. 2007;50(2):313-323.
57. Kipp B, Medeiros F, Campion MB, et al. Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study. Cancer. 2008; 114(4):228-235.
58. Frable WJ. Screening for endometrial cancer? Cancer. 2008;114(4):219-221.
59. Mitchell H, Giles G, Medley G. Accuracy and survival benefit of cytological prediction of endometrial carcinoma on routine cervical smears. Int J Gynecol Pathol. 1993;12(1):34-40.
60. Saad RS, Takei H, Liu YL, Silverman JE, Lipscomb JT, Ruiz B. Clinical significance of a cytologic diagnosis of atypical glandular cells, favor endometrial origin, in Pap smears. Acta Cytol. 2006;50(1):48-54.
61. Chieng D, Elgert P, Cohen JM, Cangierella JF. Clinical significance of atypical glandular cells of undetermined significance, favor endometrial origin. Cancer. 2001;93(6):351-356.
62. Chhieng DC, Elgert P, Cohen JM, Cangiarella JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer. 2001;93:1-7.
63. Reuss J, Price J, Koonings P. Atypical glandular cells of undetermined significance: subtyping as a poor predictor. J Reprod Med. 2001;46(8):701-705. (Pubitemid 32801990)
64. Wright TC, Massad S, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197(4):346-355.
65. Castellsagué X, Díaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006; 98(5):303-315.
66. Kalir T, Simsir A, Demopoulos HB, Demopoulos RI. Obstacles to early detection of endocervical adenocarcinoma. Int J Gynecol Pathol. 2005;24(4): 399-403.
67. Ashfaq R, Gibbons D, Vela C, Saboorian MH, Iliya F. Thin Prep Pap test: accuracy for glandular disease. Acta Cytol. 1999;43(1):81-85.
68. Schorge JO, Hossein Saboorian M, Hynan L, Ashfaq R. Thin Prep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study. Cancer. 2002;96(6):338-343.
69. Friedlander MA, Rudomina D, Lon O. Effectiveness of the Thin Prep imaging system on the detection of adenocarcinoma in the gynecologic system. Cancer. 2008;114(1):7-12.